Pallas Clinic
| Lettland | Türkei | Österreich | |
| Tomotherapie | - | von $12,000 | von $30,000 |
| Strahlentherapie bei Lungenkrebs | - | von $4,000 | von $6,913 |
| Stereotaktische Radiochirurgie | - | von $4,500 | von $17,000 |
| Protonenstrahltherapie | - | von $70,000 | von $80,000 |
| Pneumonektomie | - | von $10,872 | von $50,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Lungenkrebs-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Lungenkrebs einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Lungenkrebs-Behandlungsreise nie allein.
Über 30 Jahre Erfahrung in der Immunologie mit Schwerpunkt Virotherapie – Dr. Jaunalksne leitet das Zentrum für klinische Immunologie am Klinischen Universitätskrankenhaus Pauls Stradins.
Leading hospitals for lung cancer treatment in Latvia include the Latvian Oncology Center and Pauls Stradins Clinical University Hospital. These Riga-based institutions provide tertiary-level care. They specialize in thoracic surgery, advanced diagnostics, and multidisciplinary oncology. Private clinics like Pallas Clinic offer complementary therapies and immunotherapy.
Bookimed Expert Insight: Patients can bypass long waiting lists by starting diagnostics at private Riga clinics. Bookimed data shows specialists like Dr. Inta Jaunalksne hold dual roles in public and private sectors. Her experience at Pauls Stradins Clinical University Hospital informs the protocols at Pallas Clinic. This crossover ensures private patients receive high-level clinical expertise without the 3-month public system delays.
Patient Consensus: Patients note that while public hospitals in Riga are highly competent, diagnostic bottlenecks are common. Many recommend paying out-of-pocket for initial biopsies or scans to save critical months before starting treatment.
Advanced minimally invasive lung cancer surgeries are available in Latvia through Video-Assisted Thoracic Surgery (VATS) and innovative local destructive therapies. Specialized centers in Riga perform uniportal VATS and robotic radiosurgery. These techniques reduce physical trauma and allow for faster recovery than traditional open chest surgery.
Bookimed Expert Insight: While basic VATS is common, complex cases are concentrated in academic centers. Dr. Inta Jaunalksne at Pallas Clinic in Jūrmala provides specialized immunology that can support surgical recovery. Our data indicates patients often combine Latvian surgical expertise with these integrative protocols for personalized care.
Patient Consensus: Patients note that surgeons are honest about their experience levels with advanced techniques. Many suggest confirming the specific number of procedures a surgeon has performed before scheduling surgery.
Standard lung cancer care in Latvia integrates surgery, chemotherapy, and advanced radiation techniques like CyberKnife and proton-beam therapy. Multidisciplinary teams manage treatment protocols. These plans often combine conventional methods with immunotherapy (Pembrolizumab) and targeted therapies. Clinical centers also provide specialized biological treatments like virotherapy.
Bookimed Expert Insight: Patient data shows a distinct focus on immunology and virotherapy in Jūrmala and Riga. Dr. Inta Jaunalksne at Pallas Clinic brings over 30+ years of expertise to these integrative protocols. This specialization attracts patients seeking biological therapies alongside conventional oncology care in Latvia.
Patient Consensus: Patients note that public system wait times can reach 2-3 months. Many recommend budgeting for private services or English translators to navigate the treatment process more efficiently.
Latvia integrates multidisciplinary care for lung cancer through specialized Tumor Boards and structured Cancer Patient Pathways. These teams combine expertise from thoracic surgeons, radiologists, and oncologists to standardize treatment. Approximately 80% of Latvian cancer patients receive this coordinated, specialized medical care.
Bookimed Expert Insight: While major state hospitals focus on standard surgical and radiation protocols, private centers like Pallas Clinic in Jurmala specialize in niche supportive therapies. Dr. Inta Jaunalksne, who has over 30 years of experience, leads immunology efforts there. This allows patients to access specialized virotherapy and customized integrative plans alongside primary treatments. Choosing a facility with both established surgical teams and specialized immunologists provides the most comprehensive care coverage.
Patient Consensus: Patients emphasize the importance of confirming that a full multidisciplinary team reviews their case before starting treatment. They often recommend seeking care at larger teaching hospitals in Riga to ensure access to a wider range of specialists.
Latvia offers access to clinical trials and cutting-edge therapies through the State Agency of Medicines and European Union regulatory frameworks. Patients can access stage IV non-small cell lung cancer trials. Specialized clinics provide advanced immunotherapies, including dendritic cell therapy (DCT) and cytokine-induced killer (CIK) cell treatments.
Bookimed Expert Insight: While Latvia serves as a growing research hub, patients often face a choice between standard public care and specialized private immunology. Centers like Pallas Clinic emphasize individualized protocols that combine conventional oncology with Advanced Medical Therapeutical Products (AMTP). This integrative approach targets 100+ patients annually who seek alternatives to traditional chemotherapy-only regimens.
Patient Consensus: Patients note that while standard treatments are available, accessing the newest immunotherapy often requires moving to private clinics or traveling to larger EU hubs. Many emphasize that proactive requests are necessary, as local doctors may not always volunteer information about experimental trial options.